THX Pharma Appoints Sophie Jacq Lapointe to Accelerate International Commercialization
The biopharmaceutical company has announced the appointment of an industry executive to its Board of Directors, who has contributed to over twenty product launches at Roche, Sanofi, Sanofi Genzyme, and Ipsen. This appointment is part of THX Pharma's new strategy aimed at accelerating the registration and international commercialization of its candidates.
Over Twenty Years of Career in the Sector
Sophie Jacq Lapointe brings to THX Pharma extensive experience in the pharmaceutical and biotechnological sectors. She has held leadership and strategic roles at Roche, Sanofi, Sanofi Genzyme, and Ipsen. Among her commercial successes is the launch of Dupixent at Sanofi Genzyme, described as one of the most successful in the group in Europe. She has also contributed to over twenty product launches in France, Europe, and emerging markets.
A Reinforcement Aligned with the Company's New Trajectory
The appointment of Sophie Jacq Lapointe aligns with the strategic context of THX Pharma, which is now focused on accelerating the registration, market access, and international commercialization of its medical candidates for rare diseases. Her expertise in corporate strategy, portfolio development, and market access is expected to enhance the company's ability to progress in these areas. Mathieu Charvériat, CEO of THX Pharma, emphasizes that her commercialization experience is 'particularly in tune with the new trajectory' of the company. The appointment also follows the departure of Rodolphe Besserve from the Board of Directors.
